MSC Exosomes for COPD & Lung Conditions
Mesenchymal stem cell (MSC)-derived exosomes are studied in regenerative research for the lungs, including COPD, asthma, and pulmonary fibrosis. This overview is provided for research and educational purposes only.
What MSC exosomes are
MSC-derived exosomes are nanoscale, cell-free extracellular vesicles (roughly 30–150 nm) that carry signaling cargo such as proteins, lipids, and microRNA. They are not stem cells, and BioRegenEx supplies them as characterized, research-use-only material with per-lot documentation.
What the research explores
In preclinical respiratory models, MSC-derived exosomes have been studied for anti-inflammatory and tissue-protective signaling in COPD, asthma, acute lung injury/ARDS, and pulmonary fibrosis. These are research findings only. The studies are indexed in our Exosome Research Library under Respiratory & Lung.
Why sourcing and characterization matter
Because exosome composition depends on the source cells and manufacturing, research-grade material is defined by measurement — particle size and concentration, sterility and endotoxin screening, and a per-lot Certificate of Analysis.
Frequently Asked Questions
Are MSC exosomes an approved lung-disease treatment?
No. MSC-derived exosomes are not FDA-approved to treat this or any condition and are supplied for research use only (RUO).
What does the research focus on?
Preclinical research focuses on anti-inflammatory, anti-fibrotic, and tissue-protective signaling.
For research and educational purposes; research-use-only.
These statements have not been evaluated by the FDA. BioRegenEx supplies MSC-derived exosomes for research use only (RUO); they are not intended to diagnose, treat, cure, or prevent any disease. This content is educational and is not medical advice.